As oligonucleotide drug candidates progresses through the discovery and development phases and into clinical trials and beyond, the analytical testing strategies must also evolve. Defining each aspect of an analytical method, including data acquisition, data processing, calculations and reporting, requires consideration of the variety of approaches available. This presentation, from our expert Dr Jo-Anne Riley, Senior Scientist - Oligonucleotide Services, includes a discussion of accurate mass analysis and impurity testing. 

Please complete the form to download the slides.